Cart
sales@molnova.com
SRI 31215
CAS No. 1832686-44-8
SRI 31215( —— )
Catalog No. M20215 CAS No. 1832686-44-8
SRI 31215 a small molecule that acts as a triplex inhibitor of matriptase hepsin and HGFA and mimics the activity of HAI-1/2 endogenous inhibitors of HGF activation with IC50s of 0.69 μM 0.65 μM 0.3 μM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 79 | In Stock |
|
| 5MG | 132 | In Stock |
|
| 10MG | 205 | In Stock |
|
| 25MG | 413 | In Stock |
|
| 50MG | 617 | In Stock |
|
| 100MG | 879 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSRI 31215
-
NoteResearch use only, not for human use.
-
Brief DescriptionSRI 31215 a small molecule that acts as a triplex inhibitor of matriptase hepsin and HGFA and mimics the activity of HAI-1/2 endogenous inhibitors of HGF activation with IC50s of 0.69 μM 0.65 μM 0.3 μM.
-
DescriptionSRI 31215 a small molecule that acts as a triplex inhibitor of matriptase hepsin and HGFA and mimics the activity of HAI-1/2 endogenous inhibitors of HGF activation with IC50s of 0.69 μM 0.65 μM 0.3 μM
-
In VitroWestern Blot Analysis Cell Line:DU145 cells Concentration:10 μM Incubation Time:30 min Result:Prevented fibroblast-induced MET activation and signaling in tumor cells, but did not prevent MET activation induced by active HGF.Cell Migration Assay Cell Line:DU145 cells Concentration:10 μM Incubation Time:24 h Result:Did not interfere with HGF-induced migration, but inhibited fibroblast-induced migration of DU145 cells.
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
Targetc-Met/HGFR
-
RecptorHGFA|matriptase|hepsin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1832686-44-8
-
Formula Weight533.6
-
Molecular FormulaC27H34F3N5O3
-
Purity>98% (HPLC)
-
SolubilityDMSO:Soluble
-
SMILESOC(=O)C(F)(F)F.OC(=O)C(F)(F)F.CC1CN(CC2CCN(Cc3ccccc3)CC2)C(=O)N(C1)c1cccc(c1)C(N)=N
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Owusu BY et al. Inhibition of pro-HGF activation by SRI31215 a novel approach to block oncogenic HGF/MET signaling. Oncotarget. 2016 May 17;7(20):29492-506.
molnova catalog
related products
-
Capmatinib hydrochlo...
Capmatinib hydrochloride is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.Capmatinib was found to be highly selective for MET over other kinases.?It was active against cancer models that are characterized by MET amplification, marked MET overexpression, MET exon 14 skipping mutations, or MET activation via expression of the ligand hepatocyte growth factor (HGF).
-
Savolitinib
Savolitinib (AZD-6094) is a potent, highly selective, and orally bioavailable c-Met inhibitor with IC50s of 5 nM and 3 nM for c-Met and p-Met.
-
BMS-794833
BMS794833?is a potent ATP competitive inhibitor of Met/VEGFR2 with IC50 of 1.7 nM/15 nM.
